Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodrigo E Mendes

Showing results (211-220 of 257) with videos related to

Pageof 26
Sort By:
Journal of Chemotherapy (Florence, Italy)|November 24, 2012
ZAAPS Program results for 2010: an activity and spectrum analysis of linezolid using clinical isolates from 75 medical centres in 24 countriesRobert K Flamm, David J Farrell, Rodrigo E Mendes, et al.
Antimicrobial Agents and Chemotherapy|March 18, 2020
Ceftobiprole Activity against Bacteria from Skin and Skin Structure Infections in the United States from 2016 through 2018Robert K Flamm, Leonard R Duncan, Kamal A Hamed, et al.
Diagnostic Microbiology and Infectious Disease|September 24, 2013
Update of contemporary antimicrobial resistance rates across China: reference testing results for 12 medical centers (2011)Ronald N Jones, Mariana Castanheira, Bijie Hu, et al.
Microbial Drug Resistance (Larchmont, N.Y.)|August 1, 2015
Genotypic Characterization of Methicillin-Resistant Staphylococcus aureus Recovered at Baseline from Phase 3 Pneumonia Clinical Trials for CeftobiproleRodrigo E Mendes, Lalitagauri M Deshpande, Andrew J Costello, et al.
Diagnostic Microbiology and Infectious Disease|June 19, 2012
LEADER surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers)Robert K Flamm, David J Farrell, Rodrigo E Mendes, et al.
Diagnostic Microbiology and Infectious Disease|March 1, 2015
Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancinRonald N Jones, David J Farrell, Robert K Flamm, et al.
Jac-Antimicrobial Resistance|December 17, 2021
<i>In vitro</i> activity of a novel aminomethylcycline antibacterial (KBP-7072), a third-generation tetracycline, against clinical isolates with molecularly characterized tetracycline resistance mechanismsMichael A Pfaller, Li Li, Qingmei Liu, et al.
Open Forum Infectious Diseases|March 22, 2019
Antimicrobial Resistance Surveillance and New Drug DevelopmentHelio S Sader, Paul R Rhomberg, Andrew S Fuhrmeister, et al.
Diagnostic Microbiology and Infectious Disease|January 31, 2015
In vitro activity of linezolid as assessed through the 2013 LEADER surveillance programRobert K Flamm, Rodrigo E Mendes, Patricia A Hogan, et al.
Diagnostic Microbiology and Infectious Disease|May 22, 2022
Ceftobiprole activity against Gram-positive and Gram-negative pathogens causing bone and joint infections in the United States from 2016 to 2020Leonard R Duncan, Kamal A Hamed, Jennifer I Smart, et al.
Pageof 26

Showing results (211-220 of 257) with videos related to

Sort By:
Pageof 26
Journal of Chemotherapy (Florence, Italy)|November 24, 2012
ZAAPS Program results for 2010: an activity and spectrum analysis of linezolid using clinical isolates from 75 medical centres in 24 countriesRobert K Flamm, David J Farrell, Rodrigo E Mendes, et al.
Antimicrobial Agents and Chemotherapy|March 18, 2020
Ceftobiprole Activity against Bacteria from Skin and Skin Structure Infections in the United States from 2016 through 2018Robert K Flamm, Leonard R Duncan, Kamal A Hamed, et al.
Diagnostic Microbiology and Infectious Disease|September 24, 2013
Update of contemporary antimicrobial resistance rates across China: reference testing results for 12 medical centers (2011)Ronald N Jones, Mariana Castanheira, Bijie Hu, et al.
Microbial Drug Resistance (Larchmont, N.Y.)|August 1, 2015
Genotypic Characterization of Methicillin-Resistant Staphylococcus aureus Recovered at Baseline from Phase 3 Pneumonia Clinical Trials for CeftobiproleRodrigo E Mendes, Lalitagauri M Deshpande, Andrew J Costello, et al.
Diagnostic Microbiology and Infectious Disease|June 19, 2012
LEADER surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers)Robert K Flamm, David J Farrell, Rodrigo E Mendes, et al.
Diagnostic Microbiology and Infectious Disease|March 1, 2015
Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancinRonald N Jones, David J Farrell, Robert K Flamm, et al.
Jac-Antimicrobial Resistance|December 17, 2021
<i>In vitro</i> activity of a novel aminomethylcycline antibacterial (KBP-7072), a third-generation tetracycline, against clinical isolates with molecularly characterized tetracycline resistance mechanismsMichael A Pfaller, Li Li, Qingmei Liu, et al.
Open Forum Infectious Diseases|March 22, 2019
Antimicrobial Resistance Surveillance and New Drug DevelopmentHelio S Sader, Paul R Rhomberg, Andrew S Fuhrmeister, et al.
Diagnostic Microbiology and Infectious Disease|January 31, 2015
In vitro activity of linezolid as assessed through the 2013 LEADER surveillance programRobert K Flamm, Rodrigo E Mendes, Patricia A Hogan, et al.
Diagnostic Microbiology and Infectious Disease|May 22, 2022
Ceftobiprole activity against Gram-positive and Gram-negative pathogens causing bone and joint infections in the United States from 2016 to 2020Leonard R Duncan, Kamal A Hamed, Jennifer I Smart, et al.
Pageof 26